15500 Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices 

oral comments and presentations will be 

limited to a maximum of five minutes. 

Both printed and electronic copies are 

requested for the record. In addition, 

any interested person may file written 

comments with the Committee by 

forwarding their statement to the 

Contact Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Because of time constraints for the 

meeting, oral comments will be allowed 

on a first come, first served basis. 

Please Note: The NIH has instituted 

security measures to ensure the safety of NIH 

employees and property. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport). All visitors should be prepared 

to have their personal belongings inspected 

and to go through metal detection inspection. 

Visitors are strongly encouraged to take 

public transportation to the NIH campus, as 

there are very few visitor parking spaces 

available. NIH Building 31C is a 10-minute 

walk from the Medical Center Station on the 

Red Line of the Metro. 

A registration link and information 

about the DMICC meeting will be 

available on the DMICC Web site: 

http://www.diabetescommittee.gov. 

Members of the public who would like 

to receive e-mail notification about 

future DMICC meetings could register 

on a listserv available on the same Web 

site. 

For further information concerning 

this meeting, contact Dr. Sanford 

Garfield, Executive Secretary of the 

Diabetes Mellitus Interagency 

Coordinating Committee, National 

Institute of Diabetes and Digestive and 

Kidney Diseases, 6707 Democracy 

Boulevard, Room 654, MSC 5460, 

Bethesda, MD 20892–5460, Telephone: 

301–594–8803, fax: 301–402–6271, 

E-mail: dmicc@mail.nih.gov. 

Dated: April 1, 2009. 

Sanford Garfield, PhD, 

Executive Secretary, DMICC, Division of 

Diabetes, Endocrinology and Metabolic 

Diseases, NIDDK, National Institutes of 

Health. 

[FR Doc. E9–7724 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel Clinical Sciences. 

Date: June 22–23, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Laurie Friedman Donze, 

PhD, Scientific Review Officer, Office of 

Scientific Review, National Center for 

Complementary, and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, 301–402–1030, 

donzel@mail.nih.gov. 

Dated: March 31, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–7709 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel Loan Repayment 

Program. 

Date: April 28, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call) 

Contact Person: Laurie Friedman Donze, 

PhD, Scientific Review Officer, Office of 

Scientific Review, National Center for 

Complementary, and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, 301–402–1030, 

donzel@mail.nih.gov. 

Dated: March 31, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–7713 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Meeting 

Pursuant to Section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the National Advisory 

Council for Complementary and 

Alternative Medicine (NACCAM) 

meeting. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussion could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 


pwalker on PROD1PC71 with NOTICES